Uncontrolled AsthmaMATCHNCT03978936

Medication Adherence With Telehealthcare Medication Therapy Management

A study testing Medication Therapy Management (MTM) Video Telehealthcare and Electronic Adherence Self-Management (EAM) in people with Uncontrolled Asthma and Young Adults, run by Johns Hopkins University at 21 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Improving Medication Adherence with Telehealthcare Medication Therapy Management to Change Health Outcomes in Adolescents and Young Adults with Asthma (MATCH) is a multi-center, randomized parallel group study targeted to an at-risk population of Adolescents and Young Adults (AYA) with uncontrolled asthma who have… Read more about this study

Who is it for?: Ages 12 to 35 years
Conditions the study is for: Uncontrolled Asthma, Young Adults
What is being tested?: Medication Therapy Management (MTM) Video Telehealthcare and Electronic Adherence Self-Management (EAM)
Type of treatment: Lifestyle or therapy programme
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 375 participants
Where: 21 sitesUnited States
Study dates: 18 Nov 2019to 30 Jun 2025
Phase: Interventional
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 12 to 35 years
All sexes
No healthy volunteers
Child, Adult

Who may be able to join

Age 12 through 35 years
Speaks English or Spanish
Physician diagnosed asthma (without any other co-morbid pulmonary disease)
Prescribed ICS treatment for at least 3 months prior to screening
Adherence to Refills and Medication Scale (ARMS) 7-item questionnaire score of >8 (low or moderate adherence)
Current use of albuterol metered dose inhaler (MDI) for rescue: ProAir, Ventolin, albuterol sulfate (from Prasco or Teva)

Show all 17Show fewer

Uncontrolled asthma:
Symptomatic asthma defined as 3 of the following in the past 4 weeks:
Daytime symptoms of asthma more than twice per week
Any night awakening due to asthma
Rescue inhaler use for symptoms more than twice per week
Any activity limitation due to asthma; OR
Asthma Control Test score ≤19
Has iPhone or Android smart phone with Short Message Service (SMS)
Has access to reliable WiFi service and a device with capability for telemedicine study visits
Ability to understand and willingness to sign consent documents
Evidence of Propeller sensor connection in the 4-week run-in period

Who cannot join

Use of an investigational treatment in the previous 30 days.
Previous enrollment in MATCH Structured Interviews ( Aim 1)
Currently enrolled in an intervention trial
Currently uses an ICS not compatible with the Propeller sensor
Inability to comply with study procedures, including:
Inability or unwillingness to provide informed consent (or assent in the case of a minor).

Show all 10Show fewer

Inability to perform study measurements.
inability to be contacted by phone via calls and /or text messaging
Not willing to have video chat
Any condition(s) in the opinion of the physician that puts the participant at risk from participating in the study

Trial locations and contacts

21 sites in 1 country.

City, postcode or hospital

21 sites in 1 country

United States21 sites

University of Michigan
Ann Arbor, Michigan, 48109-5360
University of Alabama at Birmingham
Birmingham, Alabama, 35249
University of Illinois at Chicago
Chicago, Illinois, 60608
Northwestern University
Chicago, Illinois, 60611
Rush University Medical Center
Chicago, Illinois, 60612
University of Chicago Hospitals
Chicago, Illinois, 60637
Vermont Lung Center at The University of Vermont
Colchester, Vermont, 05466
National Jewish Medical and Research Center
Denver, Colorado, 80206
Duke University Medical Center
Durham, North Carolina, 27710
Baylor College of Medicine
Houston, Texas, 77030
Nemours Children's Specialty Care
Jacksonville, Florida, 32207
University of Florida College of Medicine
Jacksonville, Florida, 32209
University of Kansas Medical Center
Kansas City, Kansas, 66103
Children's Mercy Hospital
Kansas City, Missouri, 64108
New York University School of Medicine
New York, New York, 10016
Columbia University Medical Center
New York, New York, 10029
Mount Sinai National Jewish Health Respiratory Institute; Icahn School of Medicine
New York, New York, 10029
Temple University
Philadelphia, Pennsylvania, 19140
University of California at San Francisco
San Francisco, California, 94143
Pacific Northwest Airways - VA Puget Sound Healthcare System
Seattle, Washington, 98108
University of Arizona
Tucson, Arizona, 85724

Other trials in United States

About this study

Official title: Improving Medication Adherence With Telehealthcare Medication Therapy Management to Change Health Outcomes in Adolescents and Young Adults With Asthma

Read the detailed description

The study evaluates a Medication Therapy Management (MTM) video telehealthcare intervention to address poor medication adherence. In addition, it employs a novel method to track and provide feedback to participants on adherence by using Propeller Sensors. 300 adolescents and young adults will be randomized to Medication Therapy Management (MTM) video telehealthcare plus electronic adherence self-management [MTM EAM] or electronic adherence self-management alone (EAM) (also known as Digital Adherence Monitoring [DAM]). Due to the hierarchal design of the trial, two primary outcomes to be tested in a sequential manner are specified, adherence and time to first asthma exacerbation.

Conditions: Uncontrolled Asthma, Young Adults
Being tested: Medication Therapy Management (MTM) Video Telehealthcare, Electronic Adherence Self-Management (EAM)
Keywords: Asthma, Adolescents, Young adults, Controller, Medication Therapy Management, Digital monitoring, Clinical trial
Medical subject headings: Asthma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Medication Therapy Management (MTM) Video TelehealthcareBehavioural
MTM is an individualized approach to "optimize medication use for improved patient outcomes" and is designed to "empower patients to take an active role in managing patients' medications" thus, providing a favorable strategy for addressing adherence issues. Five core elements define MTM: complete medication therapy review (CMR), creation of a personal medication list (PML), development of a medication action plan (MAP), intervention and/or referral for drug therapy problems, and documentation and follow-up
Electronic Adherence Self-Management (EAM)Behavioural
Participants will have a sensor which monitors their adherence to medication use

Study groups in NCT03978936
Study group	Role	What they receive
MTM-EAM	Experimental	Medication Therapy Management Video Telehealthcare plus Electronic Adherence Self-Management [MTM-EAM] Receives: Behavioral: Medication Therapy Management (MTM) Video Telehealthcare; Behavioral: Electronic Adherence Self-Management (EAM)
EAM only	Active comparator	Electronic Adherence Self-Management [EAM] only Receives: Behavioral: Electronic Adherence Self-Management (EAM)

What is being measured

The primary outcome is the main question the study is designed to answer.

Proportion of ICS Inhaler Adherent Days
Proportion of daily adherence over the follow-up period recorded using the digital sensor on the ICS inhaler (adherence outcome) Daily ICS adherence was calculated as a proportion of sensor-recorded inhalations to the number expected based on prescribed daily dose. For primary analyses, an adherent day was defined as completion of at least 75% of prescribed inhalations, with adherence capped at 100%.
The time frame of 12 months includes a run-in period prior to randomization.
Measured: Up to 12 months
Percent Cumulative Incidence Severe Exacerbation
Percent cumulative incidence of first asthma severe exacerbation (efficacy outcome). Percent cumulative incidence of first severe asthma exacerbation was defined as a worsening of asthma requiring: (1) use of systemic corticosteroids for at least three days, (2) an emergency department visit requiring systemic corticosteroid treatment, (3) hospitalization due to asthma, or (4) death from any cause. Exacerbations were identified using biweekly My Asthma surveys, in which participants reported health-care use, medication changes, and impacts on work or school.
Measured: Up to 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

18 Nov 201930 Jun 2025

First posted7 Jun 2019
Study start18 Nov 2019
Primary completion14 Mar 2025
Study completion30 Jun 2025

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (1)Papers the sponsor has linked to this study.
Other trials for Uncontrolled AsthmaStudies of the same condition, open and under way.
More trials run by Johns Hopkins UniversityThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Supportive care
Allocation: Randomised
Intervention model: Parallel groups
Model description: Randomized, parallel, superiority trial with two intervention groups
Masking: Double blind
Who is masked: Investigator, Outcomes assessor
Enrolment: 375 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT03978936
Sponsor's protocol ID: IRB00197194
Other IDs: 1R01HL136945-01A1, 3R01HL136945-01A1S1
Acronym: MATCH
Status last verified: Jun 2026
First submitted: 5 Jun 2019
Last updated: 26 Jun 2026
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: Yes
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No

Publications

Blake KV. Telemedicine and adherence monitoring in children with asthma. Curr Opin Pulm Med. 2021 Jan;27(1):37-44. doi: 10.1097/MCP.0000000000000739.
PubMed 33105234

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

RecruitingPhase 2
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
Asthma
RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)
Asthma
RecruitingPhase 3
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
Severe Asthma
RecruitingPhase 2
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
Asthma
Active, not recruitingPhase 2
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
Asthma

All Uncontrolled Asthma trials

Study at a glance

From the registry record, last updated by the sponsor on 26 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Improving Medication Adherence With Telehealthcare Medication Therapy Management to Change Health Outcomes in Adolescents and Young Adults With Asthma
ClinicalTrials.gov ID: NCT03978936
Acronym / sponsor ID: MATCH / IRB00197194
Conditions: Uncontrolled Asthma, Young Adults
Keywords: Asthma, Adolescents, Young adults, Controller, Medication Therapy Management, Digital monitoring, Clinical trial
Study type: Interventional
Recruitment status: Completed
Enrolment: 375 participants (actual)
Lead sponsor: Johns Hopkins UniversityUniversity, hospital or other
Collaborators: Nemours Children's Health System, American Lung Association, National Heart, Lung, and Blood Institute (NHLBI)
Study start: 18 Nov 2019 (actual)
Primary completion: 14 Mar 2025 (actual)
Study completion: 30 Jun 2025 (actual)
First posted: 7 Jun 2019 (actual)
Results: Posted 26 Jun 2026

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Study design

Primary purpose: Supportive care
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind (investigator, outcomes assessor)
Number of arms: 2
Model description: Randomized, parallel, superiority trial with two intervention groups

Arm	Type	Receives
MTM-EAM	Experimental	Behavioral: Medication Therapy Management (MTM) Video Telehealthcare, Behavioral: Electronic Adherence Self-Management (EAM)Medication Therapy Management Video Telehealthcare plus Electronic Adherence Self-Management [MTM-EAM]
EAM only	Active comparator	Behavioral: Electronic Adherence Self-Management (EAM)Electronic Adherence Self-Management [EAM] only

Who may qualify

Ages: 12 to 35 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Child, Adult

Key inclusion criteria (17 listed)

Age 12 through 35 years
Speaks English or Spanish
Physician diagnosed asthma (without any other co-morbid pulmonary disease)
Prescribed ICS treatment for at least 3 months prior to screening
Adherence to Refills and Medication Scale (ARMS) 7-item questionnaire score of >8 (low or moderate adherence)

Key exclusion criteria (10 listed)

Use of an investigational treatment in the previous 30 days.
Previous enrollment in MATCH Structured Interviews ( Aim 1)
Currently enrolled in an intervention trial
Currently uses an ICS not compatible with the Propeller sensor
Inability to comply with study procedures, including:

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Medication Therapy Management (MTM) Video TelehealthcareMTM is an individualized approach to "optimize medication use for improved patient outcomes" and is designed to "empower patients to take an active role in managing patients' medications" thus, providing a favorable strategy for addressing adherence issues. Five core elements define MTM: complete medication therapy review (CMR), creation of a personal medication list (PML), development of a medication action plan (MAP), intervention and/or referral for drug therapy problems, and documentation and follow-up	Behavioural	MTM-EAM
Electronic Adherence Self-Management (EAM)Participants will have a sensor which monitors their adherence to medication use	Behavioural	EAM only, MTM-EAM

Primary outcome

Proportion of ICS Inhaler Adherent Days
Time frame: Up to 12 months
Proportion of daily adherence over the follow-up period recorded using the digital sensor on the ICS inhaler (adherence outcome) Daily ICS adherence was calculated as a proportion of sensor-recorded inhalations to the number expected based on prescribed daily dose. For primary analyses, an adherent day was defined as completion of at least 75% of prescribed inhalations, with adherence capped at 100%. The time frame of 12 months includes a run-in period prior to randomization.
Percent Cumulative Incidence Severe Exacerbation
Time frame: Up to 12 months
Percent cumulative incidence of first asthma severe exacerbation (efficacy outcome). Percent cumulative incidence of first severe asthma exacerbation was defined as a worsening of asthma requiring: (1) use of systemic corticosteroids for at least three days, (2) an emergency department visit requiring systemic corticosteroid treatment, (3) hospitalization due to asthma, or (4) death from any cause. Exacerbations were identified using biweekly My Asthma surveys, in which participants reported health-care use, medication changes, and impacts on work or school.

Results and safety

Results posted to the registry on 26 Jun 2026, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
MTM-EAM	166	130
EAM Only	155	109

Primary outcome: Proportion of ICS Inhaler Adherent Days

Time frame: Up to 12 months. Mean (95% Confidence Interval). Unit: Proportion of adherent days

Measure	MTM-EAM n = 162	EAM Only n = 149
Baseline Adherence	0.276 (0.222 to 0.331)	0.271 (0.215 to 0.328)
Randomization to Month 2 Adherence	0.350 (0.287 to 0.412)	0.281 (0.228 to 0.334)
Months 2 to 5 Adherence	0.258 (0.207 to 0.310)	0.185 (0.146 to 0.224)
Months 5 to 11 Adherence	0.187 (0.138 to 0.235)	0.107 (0.077 to 0.138)

Population analysed: Participants with data collected

Primary outcome: Percent Cumulative Incidence Severe Exacerbation

Time frame: Up to 12 months. Number (95% Confidence Interval). Unit: Percent cumulative incidence

Measure	MTM-EAM n = 164	EAM Only n = 155
Value	29.1 (20.9 to 36.4)	26.2 (18.6 to 33.0)

Population analysed: Only 319 MATCH participants (164 MTM vs. 155 EAM) had exacerbation follow-up data.

Adverse events

Time frame: Enrollment until end of follow-up, up to 1 year.. Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
MTM-EAM	6 of 166 (3.6%)	83 of 166 (50%)	0 of 166
EAM Only	14 of 155 (9%)	77 of 155 (49.7%)	0 of 155

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 26 Jun 2026.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Derived from this study: PubMed 33105234Blake KV. Telemedicine and adherence monitoring in children with asthma. Curr Opin Pulm Med. 2021 Jan;27(1):37-44. doi: 10.1097/MCP.0000000000000739.
Individual participant dataSharing planned: No

Related trials for Uncontrolled Asthma

RecruitingPhase 2
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
Asthma
RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)
Asthma
RecruitingPhase 3
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
Severe Asthma
RecruitingPhase 2
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
Asthma
Active, not recruitingPhase 2
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
Asthma

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Kathryn Blake, Pharm.D principal investigator

Nemours Children's Specialty Care

Robert Wise, MD principal investigator

Johns Hopkins School of Medicine

Janet Holbrook, PhD principal investigator

Johns Hopkins Bloomberg School of Public Health

21 sites in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 17 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 21 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 26 Jun 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of ICS Inhaler Adherent Days (time frame: Up to 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03978936, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jun 2026.